Introduction
The promyelocytic leukemia gene (PML) was originally identified as one of the two genes involved in the t(15;17) translocation in patients with acute promyelocytic leukemia (APL) (Melnick and Licht, 1999) . The PML protein is the scaffolding component of subnuclear compartments called PML nuclear bodies (NBs, also designated PML oncogenic domain or nuclear domain 10). PML NBs have been shown to play a role in a still increasing number of cellular functions including growth suppression, genomic stability, apoptosis, DNA repair, as well as transcriptional response to interferon (Salomoni and Pandolfi, 2002; Strudwick and Borden, 2002) . Taking these functions into account, it is not surprising that PML has a tumor suppressive role, and its alteration is implicated in cancer pathogenesis, including leukemia (Salomoni and Pandolfi, 2002) .
First identified as the cellular homolog to the viral oncogene of the avian myelocytomatosis virus and later as the driving oncogene in Burkitt's lymphoma, the c-Myc transcription factor is now known to be activated in about 70% of all cancers (Nilsson and Cleveland, 2003) . On the molecular level, Myc functions as a transcription factor of the basic helix-loop-helix (HLH) leucine zipper (LZ) family that can either activate or repress target genes (Eisenman, 2001; Seoane et al., 2002) . The expression level of Myc is the most important parameter determining Myc activity, with its overexpression sufficing for mitogen-independent proliferation and a terminal differentiation block (Adhikary and Eilers, 2005) . In normal cells, the expression level of Myc is tightly regulated. One of the most intriguing mechanisms of control is the rapid degradation of Myc within minutes of its synthesis by the ubiquitin-proteasome pathway (Salghetti et al., 1999) .
In APL, the PML gene is fused to the gene of retinoic acid receptor a (RARa). PML-RARa expression blocks the differentiation of hematopoietic precursor cells and is sufficient to produce leukemia in mice (Grisolano et al., 1997; He et al., 1997) . The PML-RARa fusion protein exerts its oncogenic function by interfering with the normal functions of RARa and PML. Inhibition of differentiation occurs at least in part by aberrant and constitutive repression of important differentiation genes that are usually activated by retinoic acid-bound RARa. Here, we addressed the question whether PML also has a role in differentiation, a function that might be impaired in leukemia. We show that PML increases differentiation of U937 cells by destabilizing the c-Myc transcription factor. This leads to the re-activation of Myc repressed target genes, including the cell cycle inhibitor gene p21, which contributes to PML-induced differentiation.
Results

PML synergizes with vitamin D in granulocytic differentiation
In order to test whether PML affects differentiation, we monitored granulocytic differentiation of U937 cells by flow cytometric analysis of the CD14 marker protein.
As shown in Figure 1a , inducible expression of PML potently increased differentiation in the presence of limited amounts of vitamin D, but had no influence on its own. Transforming growth factor (TGFb) exerts a similarly synergistic effect with vitamin D (Figure 1b) (Kanatani et al., 1999) suggesting that PML and TGFb might share some downstream effectors. The ability to promote differentiation was lost in a cytosolic variant of PML (cPML), which lacked the central region containing the nuclear localization sequence (Supplementary Figure 1a) .
The ability of PML to promote differentiation could either be through the activation of differentiation pathways or the inhibition of opposing factors. We reasoned that the oncogenic transcription factor Myc could be a good candidate for the latter mechanism. First, Myc was shown to partially colocalize with PML NBs (Smith et al., 2004) , and to interact with PML when co-overexpressed and in vitro (Cairo et al., 2005) . Second, overexpression of viral Myc was demonstrated to block differentiation of U937 cells (Wu et al., 2003) . Third, Myc was shown to interfere with TGFb signalling by Miz-dependent repression of genes relevant for differentiation, such as cdkn1a/p21 (Staller et al., 2001; Seoane et al., 2002) .
In order to test our hypothesis that PML might negatively regulate Myc function, we set out to confirm the interaction of the two proteins on the endogenous level, which had remained elusive until now. We found that Myc was readily detected in anti-PML immunoprecipitates after treatment of cells with proteasomal inhibitor (Figure 2a) . Interestingly, induction of the PML transgene from an inducible promoter in U937 cells resulted in a decrease in Myc levels (Figure 2b ). Cooverexpression of PML reduced the half-life of Myc, but did not affect estrogen receptor a, another short-lived receptor ( Figure 2c ). As shown in Figure 2d , overexpression of Myc partially counteracted PML and vitamin D-induced differentiation. Together, these results demonstrate that PML-mediated destabilization of Myc is intimately linked to the induction of differentiation by PML.
N-and C-terminal domains of Myc and the C-terminus of PML mediate the interaction To identify the PML domain(s) required for the interaction with Myc, we tested the ability of different deletion mutants of PML to bind Myc. As demonstrated in Figure 3a and summarized in Figure 3c , deletions of the C-terminal domain, but not of the central coiled-coil helix, abolished Myc binding. Moreover, the C-terminal part of PML was sufficient to co-precipitate Myc from lysates of co-transfected cells (Figure 3b ), thus clearly determining the C-terminus of PML as the binding interface with Myc.
On the other hand, a shortened Myc mutant truncated at amino-acid 262 retained its ability to bind PML ( Figure 4a ). This is in line with an earlier study showing that a fusion protein containing the first 178 amino acids of Myc was able to bind PML in vitro (Cairo et al., 2005) . This portion of Myc contains the Myc Box domains 1 and 2 that are known to mediate several protein-protein interactions (Eisenman, 2001) . Surprisingly, we found that also the C-terminal half of Myc retained its ability to bind PML ( Figure 4b ). As shown in Figure 4b , deletion of the HLH domain in the C-terminal half of Myc resulted in a loss of its capacity to bind PML, whereas the LZ motif was dispensable. Together, these results show that the N-terminus, as well as the C-terminal HLH domain of Myc, contributes to its interaction with PML (summarized in Figure 4c ).
PML isoform-specific binding and destabilization of Myc
The PML protein exists in seven major isoforms that are generated by alternative splicing of the messenger RNA (Jensen et al., 2001) . All PML isoforms share RING, B-box and coiled-coil domains but differ in their C-terminal regions. Focusing on these five nuclear PML isoforms, we analysed their ability to interact with Myc. In addition to PML4, which had been used if not stated otherwise, PML1 and PML2 were also able to bind Myc (Figure 5a , top panels and Figure 5e ). However, of all PML isoforms, only co-expression of PML4 resulted in a decrease of exogenous Myc levels ( Figure 5a , lower panels). Accordingly, overexpression of PML4, but not PML2, reduced the level of endogenous Myc (Figure 5b ). As shown further, deletion of the unique C-terminus of PML4 resulted in a loss of its ability to reduce Myc levels. Consistently, PML4, but neither PML2 nor the C-terminally truncated mutant, reduced the half-life of Myc (Figure 5c and d). Importantly, neither of the PML isoforms nor mutants affected the activity of the c-Myc promoter (Supplementary Figure 1b) . Together, these results show that although several PML isoforms bind to Myc, only PML4 is able to regulate the protein level of Myc by destabilizing it. Destabilization of Myc by PML depends on the integrity of its RING domain PML shares a RING domain with several proteins that function as E3 ligases in the ubiquitin-proteasome degradation pathway. Thus, we tested whether PML4 might function as a Myc-specific E3 ligase. In contrast to wild-type PML, overexpression of a RING-defective mutant, lacking two structural invariant cysteins was unable to reduce Myc levels ( Figure 6a ). In line with earlier studies that identified Myc box domains 1 and 2 and a short region partially overlapping with Myc Box 3 as sites determining Myc degradation (Salghetti et al., 1999; Herbst et al., 2004 ) the sensitivity of protein levels to PML is gradually lost by N-terminal truncation of the Myc protein ( Figure 6b ). Next, we tested whether PML would enhance ubiquitination of Myc. Coexpression of PML did not affect the amount of Myc in a pool of ubiquitinated species (Figure 6c) . In a second approach, PML did not increase the amount of poly-ubiquitinated Myc in immunoprecipitations of total Myc (Supplementary Figure 2a ). Although assay conditions of both techniques were checked with p53 by its specific E3 ligase MDM2 as positive controls (Supplementary Figure 2a and data not shown), we could not fully exclude the possibility that we might have missed PMLdependent ubiquitination of Myc owing to technical limitations. The direct interaction of an E3 ligase with an E2 enzyme is essential for its function. However, PML did not interact with any of the E2 enzyme tested (data not shown). These results show that the ability of 
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PML to destabilize Myc critically depends on the integrity of its RING domain. The data further suggest that this is not based on a function of PML as a monomeric ubiquitin E3 ligase for Myc.
Myc-repressed target genes are re-activated by PML
We addressed the question of whether increasing the level of PML affect the transcriptional regulation of Myc target genes. Although Myc-activated genes were not affected, three Myc-repressed target genes tested, gadd45, cdkn2b/p15 and cdkn1a/p21, were activated in the presence of exogenous PML (Figure 7a ). This derepression was strictly dependent on the integrity of the RING domain of PML. As further shown by chromatin immunoprecipitation (ChIP) analysis, a reduction of Myc bound to the p21 promoter was observed in presence of PML, and Myc on cdk4 was not affected (Figure 7b ). Next, we tested whether the influence of PML on differentiation of U937 cells would also be reflected on the level p21 transcription. Indeed, we found that induction of PML resulted in a strong activation of p21 in the presence as well as the absence of vitamin D (Figure 7c ), which correlated with reduction of promoter-bound Myc on p21 (Figure 7d) . Similarly, p15 was also activated by PML, albeit to a lesser extent (Supplementary Figure 3a) . Importantly, interference for p21 leads to a significant reduction of vitamin D and PML-induced differentiation (Figure 7e and Supplementary Figure 3b) . Together, these results show that the interaction of PML with Myc does not only result in a reduction of its protein levels, but also in an inhibition of its function as transcriptional repressor. Consequentially, PML induces the re-activation of genes that inhibit cell cycle and promote differentiation, such as p21. This explains how PML can potentate vitamin D-induced granulocytic differentiation of U937 cells.
Discussion
In this report, we demonstrate an important role of PML in controlling Myc stability and in turn Mycdependent transcription. We show that the PML protein contributes to granulocytic differentiation by destabilizing the Myc protein. Thereby, PML specifically interferes with Myc repression and leads to the re-activation of differentiation-relevant genes, such as cdkn1a/p21.
Although results of several experiments suggest that PML itself does not function as a ubiquitin E3 ligase for Myc, the ability of PML to destabilize Myc was clearly dependent upon the integrity of the PML RING domain. Although various PML isoforms were able to bind Myc, the ability to destabilize Myc was restricted to PML4. How can this be explained taking into account that all these PML isoforms share the RING domain and solely differ in their C-termini? The clue to this riddle could be the fact that PML proteins tend to oligomerize. Disruption of the RING domain impairs its ability to oligomerize and alters the global localization of PML (Borden et al., 1995) . Our results suggest that oligomeric PML4 complexes, rather than single PML4 molecules, mediate Myc degradation. In such a complex, one PML4 protein could serve to recruit Myc and another would bind a yet unknown factor of the Mycspecific degradation machinery. To date, two E3 ligases that specifically catalyse the rate-limiting ubiquitination step of Myc degradation have been identified: the F box protein Fbw7 and Skp2 (Amati, 2004) . We tested whether either of these could be involved in PMLdependent degradation of Myc. We could exclude Fbw7 as two phosphorylation-deficient mutants, T58A and S62A, that are rendered insensitive to Fbw7, were still degraded by PML4 (Supplementary Figure 2b) . We further did not detect any binding of Skp2 to PML4, even when both proteins were strongly overexpressed (data not shown). Hence, the factor mediating the PML-induced degradation of Myc still remains elusive. Ongoing experiments in our lab aiming at the identification of proteins bound to complexes of different PML oligomers should help to resolve that issue.
The hypothesis that at least a fraction of cellular Myc is degraded by or on PML-containing complexes is supported by several observations. First, Myc was found to concentrate on PML NBs upon inhibition of the proteasome (Smith et al., 2004) . Second, proteasomal activity and proteasomal subunits were found to be associated with the PML NB (Lafarga et al., 2002; Rockel et al., 2005) . In line with this, we found the interactions between endogenous Myc and PML proteins to be most evident after inhibition of the proteasome.
Comparing global gene expression levels of wild-type and PML-deficient MEFs, others found the set of altered genes to include a large number of Myc target genes (Cairo et al., 2005) . In line with a positive role for PML in p21 transcription, expression levels of p21 were found to be reduced in fibroblasts lacking PML. However, paradoxically, Myc target genes were found both up-and downregulated. Thus, based on these results, no clear role in Myc function could be assigned to PML. Our finding that the influence of PML on Myc critically depends on the PML isoform sheds some light on the situation. It is conceivable that the outcome of PML removal will largely depend on the identity and the stoichiometry of the PML isoforms that were initially present. Moreover, different PML isoforms might act in parallel on Myc in different pathways and/or promoters. Analyzing the exact expression profile of PML isoforms in different cell types might provide important clues on how PML can contribute to the large number of different and in part tissue-specific functions that were reported (Salomoni and Pandolfi, 2002; Strudwick and Borden, 2002) .
Our results show that the interaction of PML with Myc does not only result in a reduction of its protein levels, but also in an inhibition of its transcriptional function with some bias for repression. Taking the growth-inhibitory functions of at least two of them, cdkn2b/p15 and cdkn1a/p21, into account, PMLmediated Myc degradation could provide an important regulatory mechanism keeping Myc activity at bay and preventing aberrant rates of proliferation. In APL, the PML-RARa fusion protein exerts its oncogenic capacity by interfering with the normal functions of RARa and PML (Di Croce, 2005) . The presence of the PMLRARa fusion not only reduces the level of endogenous PML owing to the occupation of one allele, but also actively inhibits many of the normal functions of PML. Loss of PML-mediated negative regulation of Myc could thus contribute to cancer development. Understanding the regulation of Myc by PML in detail will provide another important clue for the comprehension of the complex process of carcinogenesis.
Materials and methods
Antibodies, reagents and plasmid construction Please see Supplementary Information on the Oncogene Website.
Cell culture and gene transfer Cell culture, transfections and infections were performed as described before (Buschbeck et al., 2005) . If required, positive cells were selected with 2 mg/ml puromycin or by fluorescenceactivated cell sorter (FACS) on the basis of GFP coexpression.
Zn-inducible PML-expressing U937 and control cells were described elsewhere (Fagioli et al., 1998) .
In vitro and in vivo protein analysis Immunoprecipitation and Western blot analysis were described before (Villa et al., 2006) . To study in vivo ubiquitination, two different approaches that were based either on the precipitation of the protein of interest or on the isolation of ubiquitinated species as described by Kalejta and Shenk (2003) and Treier et al. (1994) , respectively, were taken.
Gene expression analysis and chromatin immunoprecipitation
Following the supplier's instructions, RNA was purified from 2 Â 10 6 cells using the Qiagen RNeasy Mini Kit including DNAse 1 digestion to avoid potential contaminations of DNA. One microgram of total RNA was reversely transcribed into cDNA using cDNA Synthesis Kit (Roche) and oligo-dT primers. The expression of target genes of interest were quantified by real-time qPCR (Roche LightCycler) using the Light Cycler FastStart SYBR Green 1 Kit from Roche. Values were generally normalized to the expression of b-actin. Chromatin immunoprecipitations were performed and analysed essentially as described by Frank et al. (2001) . The immunoprecipitated DNA was quantified by real-time qPCR. The sequences of PCR primers and conditions chosen for amplification are available upon request.
Analysis of cell differentiation
After induction with 100 mM Zn for 12 h, cells were treated with 1 ng/ml 1a,25-dihydroxyvitamin D 3 for another 36 h. Cells were then analysed for CD14 expression by flow cytometry as described (Di Croce et al., 2002) .
Abbreviations aa, amino acids; RARa, retinoic acid receptor alpha; HA, hemagglutinin; PML, promyelocytic leukemia protein; TGFb, transforming growth factor beta.
